Advanced Search

 

Study ID Status Title Patient Level Data
116119 Completed An open label, randomized, parallel, single dose study to investigate safety and pharmacokinetics following intravenous administration and subcutaneous administration of GSK1550188 in healthy Japanese males Study Listed on ClinicalStudyDataRequest.com
116132 Completed A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5 mcg, Vilanterol 25 mcg, and Umeclidinium/Vilanterol 62.5/25 mcg Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
116133 Completed A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
116134 Completed DB2116134: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium bromide/Vilanterol Compared with Fluticasone propionate/Salmeterol Over 12 weeks in Subjects with COPD Study Listed on ClinicalStudyDataRequest.com
116135 Completed A multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide (125mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticasone propionate/salmeterol (250/50mcg) twice-daily over 12 weeks with COPD Study Listed on ClinicalStudyDataRequest.com
116136 Completed A multicenter, randomized, double-blind, parallelgroup study to evaluate the efficacy and safety of the addition of umeclidinium bromide Inhalation Powder (62.5mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide Inhalation Powder (125mcg) once-daily to fluticasone propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticasone propionate/salmeterol (250/50mcg) twice-daily over 12 weeks in subjects with COPD. Study Listed on ClinicalStudyDataRequest.com
116145 Completed Genotypic analysis of baseline and nadir HCV samples from subjects enrolled in the HBI115040 Phase I clinical trial
116146 Completed A retrospective analysis of the IL28 polymorphism of HCV-infected subjects enrolled in the HBI115040 Phase 1 clinical trial
116170 Completed A 52-Week, Open-Label, Multicenter Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination with Monotherapy of Oral Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
116197 Completed A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197) LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE (LATITUDE)-TIMI 60. Study Listed on ClinicalStudyDataRequest.com
116216 Completed An interaction study to assess the effect of the ezogabine/retigabine and the main metabolite NAMR on the pharmacokinetics of digoxin in healthy volunteers Study Listed on ClinicalStudyDataRequest.com
116239 Completed An observational cohort study to assess the risk of autoimmune diseases in adolescent and young adult women aged 9 to 25 years exposed to Cervarix® in the United Kingdom
116266 Terminated A Three-Part Phase I, Open-Label, Single Ascending Dose, and A Single-Blind, Placebo-Controlled, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability of Intravenous and Oral GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects Study Listed on ClinicalStudyDataRequest.com
116318 Completed Plan for Re-Evaluation of Sudden Unexplained Death in Epilepsy (SUDEP) Occurring in the Lamotrigine Clinical Development Program
116344 Completed PGx471: Combined pharmacogenetic analysis of IL28B genotypes in TPL108390 and TPL103922
116371 Completed A Phase 1, Open-Label, Crossover Study to Demonstrate the Bioequivalence of RYTHMOL SR® (propafenone hydrochloride) Manufactured at Two Different Sites Study Listed on ClinicalStudyDataRequest.com
116402 Completed A multi-national, randomized, double-blind, placebo-controlled, 3-period crossover study with GSK 573719 as monotherapy in adult subjects with asthma Study Listed on ClinicalStudyDataRequest.com
116415 Completed A randomized, double-blind, single dose, four way cross-over study to assess the systemic exposure, systemic pharmacodynamics and safety and tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol following single inhaled doses of Umeclidinium/Vilanterol blend + Fluticasone Furoate, Umeclidinium + Vilanterol, Fluticasone Furoate + Vilanterol and Fluticasone Furoate + Umeclidinium in healthy subjects Study Listed on ClinicalStudyDataRequest.com
116416 Completed Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects Study Listed on ClinicalStudyDataRequest.com
116477 Completed Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis Study Listed on ClinicalStudyDataRequest.com
116490 Completed REMS Prescriber and Pharmacist Understanding of the Risk of Urinary Retention with POTIGA™
116511 Completed A single blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, tolerability,pharmacokinetic and pharmacodynamic parameters of repeat doses of GSK2330672 in healthy volunteers, given alone and with a single day of dosing with GSK1614235 Study Listed on ClinicalStudyDataRequest.com
116524 Completed A randomized, double blind, single-dose, three-period, crossover study to investigate pharmacokinetic, safety and tolerability of Fluticasone Furoate with Umeclidinium when administered in combination and as monotherapies in adult healthy volunteer subjects Study Listed on ClinicalStudyDataRequest.com
116554 Completed Incident Type II Diabetes Mellitus Among Patients Exposed to the Combination of Pravastatin and Paroxetine
116592 Completed A randomized, double-blind, placebo-controlled cross-over study to determine the bronchodilator effect of a single dose of fluticasone furoate (FF)/ vilanterol (VI) 100/25 mcg combination administered in the morning in adult patients with asthma Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.